Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Cobolimab |
Trade Name | |
Synonyms | TSR-022 |
Drug Descriptions |
Cobolimab (TSR-022) is a monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2504). |
DrugClasses | Immune Checkpoint Inhibitor 153 TIM-3 Antibody 8 |
CAS Registry Number | 2022215-65-0 |
NCIT ID | C128627 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cobolimab | Cobolimab | 0 | 1 |
Cobolimab + Docetaxel + Dostarlimab-gxly | Cobolimab Docetaxel Dostarlimab-gxly | 0 | 1 |
Cobolimab + Dostarlimab-gxly | Cobolimab Dostarlimab-gxly | 0 | 2 |
Cobolimab + unspecified PD-1 antibody | Cobolimab unspecified PD-1 antibody | 0 | 1 |